Tetracycline
drug drugOn this page
Also known as Achromycin vE701EconomycinNSC-108579PanmycinSupramycinSustamycinTetrabid organonTetraciclinaTetracycline component of pyleraVetquamycinTetracyclinSID855950SID144210470C0164578TETRACYCLINE HYDROCHLORIDE
Summary
Tetracycline (CHEMBL1440) is an approved small-molecule antimicrobial agent (ATC D06AA04); indicated across 17 conditions including bacterial infectious disease and eye infectious disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D06AA04 (+5 more)
- Indications: 17 conditions
- Clinical trials: 69
- Chemistry: C22H24N2O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1440 |
| Name | Tetracycline |
| Type | Small molecule |
| Max phase | 4 |
| ChEBI | CHEBI:27902 |
| ATC | D06AA04, S03AA02, S01AA09, S02AA08, A01AB13, J01AA07 |
| Molecular formula | C22H24N2O8 |
| InChIKey | OFVLGDICTFRJMM-WESIUVDSSA-N |
SMILES: [H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)c1c(O)cccc1[C@@]2(C)O
ChEBI definition: A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.
Pharmacological roles (ChEBI): antimicrobial agent, antibacterial drug, antiprotozoal drug, protein synthesis inhibitor.
Other ChEBI roles (chemical / environmental): Escherichia coli metabolite.
Also known as: Achromycin v, E701, Economycin, NSC-108579, Panmycin, Supramycin, Sustamycin, Tetrabid organon, Tetraciclina, Tetracycline, Tetracycline component of pylera, Vetquamycin
Parent form; salt/anhydrous children: CHEMBL454950, CHEMBL1201071
Patent coverage: 103,434 distinct patent families (324,384 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 320,366 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Heat shock protein HSP90, Tyrosine-protein phosphatase non-receptor type 7, Sodium-dependent noradrenaline transporter, Bacterial 70S ribosome, Sodium-dependent dopamine transporter, Androgen receptor, Multidrug transporter MdfA, Alpha-synuclein.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P02358 | 5.34 | IC50 | 4580 | nM | CHEMBL_ACT_8036359 |
| SNCA | 5.22 | IC50 | 6060 | nM | CHEMBL_ACT_22754657 |
| PTPN7 | 5.08 | IC50 | 8330 | nM | CHEMBL_ACT_3774611 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
11 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| periodontitis | 3 | MONDO:0005076 | EFO:0000649 |
| Helicobacter pylori infectious disease | 3 | MONDO:0006781 | EFO:1000961 |
| bacterial vaginosis | 3 | MONDO:0005316 | EFO:0003932 |
| vulvovaginal candidiasis | 3 | MONDO:0006014 | EFO:0007543 |
| inclusion conjunctivitis | 3 | MONDO:0005808 | EFO:0007324 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| burn | 2 | MONDO:0043519 | EFO:0009516 |
| Lyme disease | 2 | MONDO:0019632 | EFO:0008510 |
| chronic progressive multiple sclerosis | 1 | MONDO:0005284 | EFO:0003840 |
| relapsing-remitting multiple sclerosis | 1 | MONDO:0005314 | EFO:0003929 |
| multiple sclerosis | 1 | MONDO:0005301 | MONDO:0005301 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 69.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 38 |
| Not specified | 17 |
| PHASE3 | 5 |
| PHASE2 | 5 |
| EARLY_PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04527055 | PHASE4 | ENROLLING_BY_INVITATION | The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication |
| NCT05061732 | PHASE4 | RECRUITING | Helicobacter Pylori Eradication and Follow-up |
| NCT05874570 | PHASE4 | RECRUITING | Doxycycline for Helicobacter Pylori Rescue Treatment |
| NCT06168214 | PHASE4 | RECRUITING | Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication |
| NCT06509139 | PHASE4 | ENROLLING_BY_INVITATION | Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males |
| NCT06723197 | PHASE4 | RECRUITING | Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication |
| NCT07139366 | PHASE4 | RECRUITING | Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment |
| NCT00336154 | PHASE4 | WITHDRAWN | Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa |
| NCT00347776 | PHASE4 | COMPLETED | Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia |
| NCT00841854 | PHASE4 | COMPLETED | Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication |
| NCT01668927 | PHASE4 | COMPLETED | Empirical Rescue Therapies of Helicobacter Pylori Infection |
| NCT01742429 | PHASE4 | COMPLETED | Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection |
| NCT01753856 | PHASE4 | COMPLETED | Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis |
| NCT01792700 | PHASE4 | COMPLETED | Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy |
| NCT02175927 | PHASE4 | COMPLETED | High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection |
| NCT02576652 | PHASE4 | COMPLETED | Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement |
| NCT02988089 | PHASE4 | UNKNOWN | Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment |
| NCT03139253 | PHASE4 | UNKNOWN | Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment |
| NCT03208426 | PHASE4 | UNKNOWN | Sequential Versus Quadruple Therapy in the Second-line Treatment |
| NCT03555526 | PHASE4 | UNKNOWN | Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection |
| NCT03609892 | PHASE4 | COMPLETED | Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy |
| NCT03616405 | PHASE4 | UNKNOWN | Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection |
| NCT03658733 | PHASE4 | UNKNOWN | A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection |
| NCT03708848 | PHASE4 | COMPLETED | Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy |
| NCT04531059 | PHASE4 | COMPLETED | Rescue Therapy for Helicobacter Pylori Eradication Treatment |
| NCT04678492 | PHASE4 | COMPLETED | Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy |
| NCT04853875 | PHASE4 | COMPLETED | ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin |
| NCT04901117 | PHASE4 | UNKNOWN | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days |
| NCT05018923 | PHASE4 | UNKNOWN | Tetracycline Versus Doxycycline for HP Rescue Therapy |
| NCT05049902 | PHASE4 | COMPLETED | Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication |
| NCT05250050 | PHASE4 | UNKNOWN | Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment |
| NCT05345210 | PHASE4 | UNKNOWN | Vonoprazan Hp Dual or Triple Eradication Regimes |
| NCT05432115 | PHASE4 | UNKNOWN | Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies. |
| NCT05874544 | PHASE4 | COMPLETED | Rescue Therapy for Helicobacter Pylori Infection |
| NCT06168084 | PHASE4 | COMPLETED | Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy |
| NCT06351891 | PHASE4 | UNKNOWN | Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin |
| NCT06561711 | PHASE4 | COMPLETED | Optimization of Minocycline for Helicobacter Pylori Rescue Treatment |
| NCT06695559 | PHASE4 | COMPLETED | Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry |
| NCT00591162 | PHASE2/PHASE3 | TERMINATED | Bone Disease in Severely Burned Children |
| NCT01098448 | PHASE3 | COMPLETED | Control of Periodontal Infections |
| NCT01293643 | PHASE3 | COMPLETED | A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) |
| NCT01481844 | PHASE3 | COMPLETED | Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection |
| NCT02754583 | PHASE3 | COMPLETED | Sanitation, Water, and Instruction in Face-washing for Trachoma I/II |
| NCT04107194 | PHASE3 | UNKNOWN | Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection. |
| NCT05219929 | PHASE2 | ENROLLING_BY_INVITATION | Tetracycline Treatment Tolerability Trial |
| NCT00002682 | PHASE2 | COMPLETED | Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach |
| NCT00003151 | PHASE2 | COMPLETED | Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma |
| NCT01880515 | PHASE2 | COMPLETED | Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib) |
| NCT03632733 | PHASE2 | UNKNOWN | Effects of Antimicrobials on the Altered Skin Flora in Arsenical Keratosis |
| NCT04066257 | PHASE1 | COMPLETED | Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers |
| NCT06225570 | EARLY_PHASE1 | RECRUITING | Weekly Isotretinoin vs Tetracycline for Moderate Acne |
| NCT01763437 | EARLY_PHASE1 | WITHDRAWN | Intralesional Tetracycline Injection in the Treatment of Chalazia |
| NCT07358130 | Not specified | RECRUITING | Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy |
| NCT00091247 | Not specified | COMPLETED | Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer |
| NCT00873808 | Not specified | WITHDRAWN | S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 |
| NCT02159976 | Not specified | COMPLETED | Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea |
| NCT02359331 | Not specified | TERMINATED | The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection |
| NCT03494972 | Not specified | COMPLETED | A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery |
| NCT03611920 | Not specified | COMPLETED | Effect of Topical Tetracycline and Dexamethasone on Periodontal and Pulpal Regeneration of Replanted Avulsed Teeth |
| NCT03634605 | Not specified | COMPLETED | Effect of Tetracycline Pleurodesis on Prevention of Primary Spontaneous Pneumothorax Recurrence |
| NCT03908892 | Not specified | UNKNOWN | Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib |
| NCT04716426 | Not specified | COMPLETED | APT™ T3X on the COVID-19 Contamination Rate |
| NCT04721626 | Not specified | COMPLETED | Topical Antisepsis in Head and Neck Cancer Surgery |
| NCT04879992 | Not specified | COMPLETED | Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori |
| NCT04991584 | Not specified | UNKNOWN | Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection |
| NCT05173493 | Not specified | COMPLETED | The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure |
| NCT05620589 | Not specified | UNKNOWN | The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection |
| NCT06759610 | Not specified | COMPLETED | Effect of Tetracycline Socked Pack on Acceleration of Healing During Marsupialization |
| NCT06977841 | Not specified | COMPLETED | Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: bacterial infectious disease, eye infectious disorder
- In clinical trials for: periodontitis, Helicobacter pylori infectious disease, bacterial vaginosis, vulvovaginal candidiasis, inclusion conjunctivitis, non-Hodgkin lymphoma, burn, Lyme disease